Scope of the Report

The report titled “Global Age-Related Macular Degeneration (AMD) Market: Trends & Opportunities (2013-2018)” provides an in-depth analysis of the global age-related macular degeneration market with detailed analysis of various countries like the United States, U.K, Australia. It also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall AMD market has also been forecasted for the period 2013-2018, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. Further, key players of the industry like Norvatis, Regeneron, Roche and Bayer are profiled.

Regional Coverage

- U.S
- U.K
- Australia
Company Coverage

- Norvatis
- Regeneron
- Roche
- Bayer
Executive Summary

Age-related macular degeneration (AMD) is a condition affecting older people, and involves the loss of the person's central field of vision. Several forms of AMD exist such as early AMD, late AMD, dry AMD, Wet AMD etc. Globally, the disease ranks third as a cause of blindness after cataract and glaucoma. The main factor is ageing and other risk factors may include the use of tobacco, genetic tendencies, the degree of pigmentation (with light colored eyes being at higher risk), arterial hypertension, the ultraviolet rays, and consumption of a non-balanced diet. As for the cure of the disease, there is at present no definitive treatment. Palliative treatments which are able to retard the progress of the disease include the use of intravitreous drugs or injections, lasers, dynamic phototherapy and sometimes surgery.

Globally the prevalence of AMD disease is highest in the U.S followed by the U.K and Australia. The world’s elderly population is the fastest growing age group; this is the main reason for the rising prevalence of AMD. Rising smoking habit, and unhealthy diet are the other reasons which will increase the count of AMD affected people in the near future. New types of drugs such as Eylea have come up which is indicated for the treatment of patients with neovascular (wet) age related macular degeneration and expected to substitute Lucentis and Avastin drugs in the coming years.
Age-related macular degeneration (AMD) is a medical condition which usually affects older adults and results in a loss of vision in the center of the visual field (the macula) because of damage to the retina.

- Global AMD market size is expected to reach to US$ ...... million in the year 2018, from ....... in 2012 by growing at a CAGR of .......%.
- Growth in the market is due to ..................................................
• .......... accounted for ....% share of the global AMD market in the year 2012, while .......... accounts for ........% of the market share

• In 2011, around .......% of the total market share of global AMD market was held by ..........
Market Trends

Radiation Therapy Treatment for AMD

- .................................................................
- .................................................................
- .................................................................
- .................................................................

New Drugs Eylea for the Treatment of AMD

- .................................................................
- .................................................................
- .................................................................
- .................................................................